Onconic Therapeutics Marks a Milestone with Nesuparip Patent

Onconic Therapeutics has proudly announced the granting of a use patent in Australia for its innovative dual-target anticancer drug, Nesuparip. This patent, valid until May 18, 2042, signifies a major advancement in treating PARP inhibitor-resistant cancers.

Revolutionizing Cancer Treatment

Nesuparip stands out as a next-generation synthetic lethality-based drug, offering a novel approach by simultaneously inhibiting PARP and tankyrase. This dual-action mechanism not only targets DNA repair but also impedes cancer growth, presenting a promising solution for solid tumors across various cancer types.

Expanding Horizons in Cancer Therapy

With ongoing phase 1b/2 and phase 2 clinical trials for pancreatic and endometrial cancer, and rare disease designations from the FDA and Korean Ministry of Food and Drug Safety, Onconic is at the forefront of anticancer innovation. The company is also exploring combination therapies with leading drugs like Keytruda and Vegzelma to broaden treatment options.

A Vision for the Future

"This patent not only secures our progressiveness but also opens new avenues for patients with limited treatment options," stated an Onconic representative. The global filing of this patent across 21 countries underscores Onconic's commitment to addressing unmet needs in the global anticancer drug market.